Treatment for Rheumatoid Arthritis Associated With Alterations in the Gastrointestinal Microbiota

Kristofer Andréasson, Tor Olofsson, Venu Lagishetty, Zaid Alrawi, Eline Klaassens, Savanne Holster, Roger Hesselstrand, Jonathan P. Jacobs, Johan K. Wallman, Elizabeth R. Volkmann

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: Emerging research suggests that rheumatoid arthritis (RA) is associated with intestinal dysbiosis. This prospective pilot study evaluates changes in intestinal microbial composition in patients with RA initiating treatment with either methotrexate (MTX) or a tumor necrosis factor inhibitor (TNFi). Methods: Consecutive patients, fulfilling the 2010 American College of Rheumatology/EULAR classification criteria for RA, who started treatment with either MTX or TNFi delivered a stool sample upon initiation of immunosuppression and 3 months later. A 16S ribosomal RNA gene-based validated microbiota test (GA-map Dysbiosis Index Score [DIS], Genetic Analysis, Oslo, Norway) was used to evaluate for the presence and degree of dysbiosis. Fecal levels of Prevotella copri (P. copri) were analyzed by custom-made quantitative polymerase chain reaction. Changes in microbial composition were analyzed in relation to changes in disease activity, as measured by the disease activity score based on 28-joint counts, using C-reactive protein. Results: At baseline, dysbiosis was present in 33 of 50 (66%) participants and more common in participants with more than 2 years of disease duration (P = 0.019). At the 3-month follow-up, 27 of 50 (54%) were good treatment responders and the DIS had improved in 14 of 50 (28%). Participants initiating TNFi more often exhibited improvement in the DIS compared with those initiating MTX (P = 0.031). P. copri was identified in 32 of 50 (64%) at baseline. An improvement in disease activity score based on 28-joint counts, using C-reactive protein was associated with a simultaneous decrease in P. copri abundance (rs = 0.30, P = 0.036). Conclusion: This study affirms that dysbiosis is a feature of RA. Although patients were not randomized to MTX or TNFi, the findings suggest that specific therapies may differentially modulate the gastrointestinal microbiota in RA. The association between P. copri and treatment response requires further study.

Original languageEnglish
JournalACR Open Rheumatology
DOIs
Publication statusAccepted/In press - 2024

Subject classification (UKÄ)

  • Rheumatology and Autoimmunity

Fingerprint

Dive into the research topics of 'Treatment for Rheumatoid Arthritis Associated With Alterations in the Gastrointestinal Microbiota'. Together they form a unique fingerprint.

Cite this